Press Release: Invivyd Reports Third Quarter 2026 Financial Results and Recent Business Highlights

Dow Jones11-16 20:01
   -- DECLARATION Phase 3 clinical trial data on VYD2311 (ibramvibart) to be 
      available imminently, per the Accelerated Approval analysis and 
      regulatory submission plan previously communicated 
 
   -- Updated data timing driven by dialogue between Invivyd and the U.S. FDA 
      1) to refine details on the Accelerated Approval approach for VYD2311, 
      and 2) to expand the accelerated regulatory approach and enable rapid 
      development of future Invivyd monoclonal antibodies, including Invivyd's 
      measles antibody candidate; further update to be provided with 
      DECLARATION interim analysis data 
 
   -- Achieved Q3 2026 PEMGARDA(R) (pemivibart) net product revenue of $15.4 
      million, representing 18% growth versus Q3 2025 net product revenue of 
      $13.1 million 
 
   -- Appointed Chairman Marc W. Elia as Chief Executive Officer 
 
   -- Announced positive topline results from LIBERTY Phase 3 clinical trial, 
      which demonstrated VYD2311 safety and tolerability superior to an 
      mRNA-based COVID-19 vaccine and lack of interference with vaccine-induced 
      neutralizing antibody titers 
 
   -- Announced initiation of FLINTLOCK Phase 2 clinical trial of VYD2311, 
      which will evaluate VYD2311 in adults aged 18-65 years with Long COVID or 
      Post-Vaccination Syndrome, also known as COVID vaccine injury 
 
   -- Investments being made in commercial preparedness for VYD2311; Invivyd 
      plans to host a Medical and Commercial Investor Event in 1H 2027 to 
      describe commercial plans and early expressions of institutional demand 
 
   -- Q3 2026 ending cash and cash equivalents of $126.4 million 

NEW HAVEN, Conn., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced financial results for the third quarter ended September 30, 2026, and recent business highlights.

"We are excited about the progress made to advance VYD2311 to meet the urgent need for new options to prevent Americans from getting sick from COVID and suffering from the debilitating impact of Long COVID or COVID vaccine injury," said Marc Elia, Chairman and Chief Executive Officer of Invivyd. "While our DECLARATION data readout timing has been updated as we continued to work with regulators and policymakers on immunization regulation in America broadly, we are pleased that U.S. regulators understand the important role monoclonal antibodies can play in infectious disease going forward. We look forward to providing DECLARATION data and a regulatory update imminently, and we appreciate investor patience as we endeavor to set the stage for anticipated rapid advancement should VYD2311 DECLARATION data demonstrate an attractive clinical profile."

"PEMGARDA's continued growth, even in the face of declining COVID vaccine utilization and announcement of the termination of its Emergency Use Authorization in mid-2027, demonstrates clear demand for monoclonal antibodies," commented Bill Duke, Chief Financial Officer of Invivyd. "With a bolus of REVOLUTION clinical program spend in the rear view at this time, we look forward to a new posture of increased operating efficiency while we work to bring VYD2311 to vulnerable Americans as fast as possible."

Third Quarter 2026 and Recent Company Highlights

PEMGARDA(R) Commercial Performance & Regulatory Update

   -- PEMGARDA net product revenue was $15.4 million for the quarter ended 
      September 30, 2026, compared to $13.1 million for the quarter ended 
      September 30, 2025. Growth of 18% was driven primarily by increased 
      patient demand. 
 
   -- In July 2026, Invivyd announced receipt of twelve months' advanced notice 
      of emergency use authorization (EUA) termination for PEMGARDA and that 
      the company is in dialogue with the U.S. Food and Drug Administration 
      (FDA) about appropriate next steps. 

Research & Development (R&D) Highlights

COVID-19

   -- Invivyd continued to advance its REVOLUTION program, which is Invivyd's 
      development program for VYD2311 that is designed to elaborate the profile 
      of monoclonal antibody-mediated prophylaxis from COVID-19 and the 
      potential medical benefits to vulnerable Americans: 
 
          -- LIBERTY: In June 2026, Invivyd announced first participants dosed 
             and completion of enrollment in LIBERTY, a Phase 3 clinical trial 
             to evaluate the safety and tolerability of VYD2311 antibody versus 
             mRNA COVID vaccine and to characterize the safety and immunology 
             of antibody and mRNA vaccine co-administration. In September 2026, 
             Invivyd announced positive topline results from LIBERTY 
             demonstrating VYD2311 safety and tolerability superior to an 
             mRNA-based COVID-19 vaccine: 
 
                 -- VYD2311 met all primary and secondary endpoints comparing 
                    VYD2311 to an mRNA-based COVID-19 vaccine, demonstrating 
                    VYD2311 safety and tolerability that is clinically and 
                    statistically superior to the safety and tolerability of an 
                    mRNA-based COVID-19 vaccine. 
 
                 -- VYD2311 combined with an mRNA-based COVID-19 vaccine 
                    demonstrated no interference with vaccine-induced 
                    neutralizing titers and instead added substantially to 
                    vaccine-induced neutralizing titers. 
 
                 -- VYD2311 observed profile in LIBERTY indicates high measured 
                    neutralizing antiviral titers supporting the target profile 
                    for VYD2311 under study in the DECLARATION pivotal clinical 
                    study. 
   -- DECLARATION: In September 2026, Invivyd announced plans for the 
      DECLARATION Phase 3 clinical trial, with support from the LIBERTY 
      clinical trial and reference to prior Invivyd COVID-19 mAb data, to be 
      the basis of a planned Biologics License Application (BLA) submission for 
      VYD2311 to the FDA under the Accelerated Approval Program. Invivyd plans 
      to conduct a prespecified interim analysis in DECLARATION designed to 
      evaluate serum virus neutralizing antibody titers, pharmacokinetics, 
      immunogenicity, and safety of VYD2311, while keeping blinded the clinical 
      events collected to date. These analyses are intended to support a BLA 
      submission under the Accelerated Approval Program, with the interim data 
      expected imminently. Invivyd plans to continue the DECLARATION study to 
      serve as the confirmatory trial, with DECLARATION continuing to collect 
      RT-PCR-confirmed symptomatic COVID-19 events. Clinical event data from 
      DECLARATION will serve, if the study is positive, as confirmatory 
      evidence for conversion to traditional approval of VYD2311. 
   -- FLINTLOCK: In January 2026, Invivyd and the SPEAR (Spike Protein 
      Elimination and Recovery) Study Group announced the plan to initiate a 
      Phase 2 clinical trial evaluating VYD2311 in individuals with Long COVID 
      or COVID vaccine injury. In October 2026, Invivyd and the SPEAR Study 
      Group announced initiation of FLINTLOCK. 
 
          -- FLINTLOCK Phase 2 clinical trial will evaluate the safety, 
             tolerability, pharmacokinetics, and clinical efficacy of high-dose 
             VYD2311 in adults aged 18-65 years with Long COVID or 
             Post-Vaccination Syndrome, also known as COVID vaccine injury. 
 
          -- Design includes VYD2311 administered in three doses to assess the 
             safety and potential clinical benefit of VYD2311 treatment versus 
             placebo over 90 days. 

Measles

   -- In October 2026, Invivyd presented VMS063, a novel, potential first-and 
      best-in-class monoclonal antibody investigational candidate for the 
      treatment and prevention of measles, at IDWeek 2026(TM). VMS063 
      preclinical data has demonstrated potent in vitro antiviral activity 
      against contemporary measles virus variants and attractive biophysical 
      properties supporting its potential utility for both treatment and 
      prevention of measles. Invivyd is scaling up production toward clinical 
      development in 2027. 

Corporate Updates

   -- In September 2026, Invivyd announced the appointment of Marc Elia, 
      Chairman of Invivyd's Board of Directors (the Board), as Chief Executive 
      Officer of Invivyd. In addition, Invivyd announced Ajay Royan, Founder of 
      Mithril Capital, a founding, long-term investor of Invivyd, and a member 
      of the Board, was appointed as Lead Independent Director of the Board, 
      and Ian Sheffield was appointed to the Board as an independent director. 

Third Quarter 2026 Financial Results

   -- Revenue: Reported Q3 2026 PEMGARDA net product revenue of $15.4 million, 
      compared to $13.1 million in Q3 2025, representing an 18% increase. 
 
   -- Cash Position: Cash and cash equivalents were $126.4 million as of 
      September 30, 2026. 
 
   -- R&D Expenses: R&D expenses were $18.7 million for the quarter ended 
      September 30, 2026, compared to $8.0 million for the comparable period in 
      2025. This increase is primarily attributable to higher contract research 
      costs associated with the DECLARATION and LIBERTY clinical trials for 
      VYD2311. 
 
   -- Selling, General & Administrative (SG&A) Expenses: SG&A expenses were 
      $30.3 million for the quarter ended September 30, 2026, compared to $15.0 
      million for the comparable period in 2025. This increase is primarily 
      attributable to an increase in personnel, communications and 
      commercial-related costs. 
 
   -- Net Loss and Net Loss per Share: Net loss was $33.5 million for the 
      quarter ended September 30, 2026, compared to $10.5 million for the 
      comparable period in 2025. Basic and diluted net loss per share was $0.10 
      for the quarter ended September 30, 2026, compared to $0.06 for the 
      comparable period in 2025. 

About PEMGARDA

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment